InvestorsHub Logo
Followers 0
Posts 5
Boards Moderated 0
Alias Born 03/18/2014

Re: None

Monday, 03/23/2015 6:37:00 PM

Monday, March 23, 2015 6:37:00 PM

Post# of 716563
I find it very discouraging how Pyrr is getting attacked on this board. In the end, if you don't like what he has to say then simply ignore him. Lets all remember that Pyrr has been active on this board for a long time, he's had some good insights, he's been right on some things and wrong on some things. He's not a scientist and clearly states he's not. Its anyone guess to what his motives are. Let him trade this stock how he wants. As to DcVax-L, it will get approved, coming from a science background, it's an inevitable event. But that doesn't mean commercial success. If L only prolongs survival by a couple months, then it will be a failure. We all need to remember that this technology is very labor intensive and more importantly expensive. Patients have to go through multiple procedures that are costly in the clinical setting. A lot of people on this board seem to lose the forest through the trees in this respect. The recent rGBM arm data doesn't look as promising as I had hoped. 15.1 months is not good enough. However, this is not the data that counts, if the phase III L trial does show a significant increase in survival, on the level of 12 months or so, then this stock will rocket plain and simple. I don't really understand this talk about the RECIST criteria either, of course Direct results will be scrutinized using this criteria, its the gold standard right now and will be for years.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News